From Cause to Consequence: Insights into Incident Diabetes Mellitus After Hepatic Steatosis

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2023 Mar 20

PMID 36938314

Authors

Manik Aggarwal

Christina C Lindenmeyer

Affiliations

Soon will be listed here.

Citing Articles

MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development.

Khaznadar F, Khaznadar O, Petrovic A, Hefer M, Gjoni F, Gjoni S Curr Issues Mol Biol. 2024; 46(7):6300-6314.

PMID: 39057018 PMC: 11275123. DOI: 10.3390/cimb46070376.

References

Li A, Ahmed A, Kim D . Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut Liver. 2019; 14(2):168-178. PMC: 7096231. DOI: 10.5009/gnl19069. View

Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G . Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008; 19(8):1564-70. PMC: 2488256. DOI: 10.1681/ASN.2007101155. View

Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G . Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites. 2021; 11(2). PMC: 7911747. DOI: 10.3390/metabo11020073. View

Newsome P, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V . A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2020; 384(12):1113-1124. DOI: 10.1056/NEJMoa2028395. View

Morrison A, Zaccardi F, Khunti K, Davies M . Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. Liver Int. 2018; 39(3):557-567. DOI: 10.1111/liv.13994. View

Kim C, Park J, Lee K, Kim J, Kim H . Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008; 25(4):476-81. DOI: 10.1111/j.1464-5491.2008.02410.x. View

Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough A . Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107(5):450-5. DOI: 10.1016/s0002-9343(99)00271-5. View

Zhang C, Zhou B, Sheng J, Chen Y, Cao Y, Chen C . Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res. 2020; 159:104984. DOI: 10.1016/j.phrs.2020.104984. View

Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne C, Targher G . Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2020; 70(5):962-969. DOI: 10.1136/gutjnl-2020-322572. View

10.

Adams L, Harmsen S, St Sauver J, Charatcharoenwitthaya P, Enders F, Therneau T . Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010; 105(7):1567-73. PMC: 2898908. DOI: 10.1038/ajg.2010.18. View

11.

Arab J, Arrese M, Trauner M . Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annu Rev Pathol. 2018; 13:321-350. DOI: 10.1146/annurev-pathol-020117-043617. View

12.

Younossi Z, Golabi P, de Avila L, Paik J, Srishord M, Fukui N . The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019; 71(4):793-801. DOI: 10.1016/j.jhep.2019.06.021. View

13.

Cho H, Hwang S, Park J, Yang M, Hwang J, Yoo B . Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. Gut Liver. 2019; 13(4):440-449. PMC: 6622569. DOI: 10.5009/gnl18382. View

14.

Targher G, Corey K, Byrne C, Roden M . The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021; 18(9):599-612. DOI: 10.1038/s41575-021-00448-y. View

15.

Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F . Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. J Clin Med. 2022; 11(4). PMC: 8878156. DOI: 10.3390/jcm11040968. View

16.

Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R . Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007; 133(2):496-506. DOI: 10.1053/j.gastro.2007.04.068. View

17.

Xu Q, Zhang J, Han H, Chen N, Lai F, Liu Y . Association between intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity and risks of pre-diabetes plus diabetes: an observational study. BMJ Open. 2022; 12(2):e057820. PMC: 8862459. DOI: 10.1136/bmjopen-2021-057820. View

18.

Lee J, Cho Y, Kang Y, Kim H, Jung C, Kim H . The Impact of NAFLD and Waist Circumference Changes on Diabetes Development in Prediabetes Subjects. Sci Rep. 2019; 9(1):17258. PMC: 6872574. DOI: 10.1038/s41598-019-53947-z. View

19.

Ter Horst K, Gilijamse P, Versteeg R, Ackermans M, Nederveen A, la Fleur S . Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans. Cell Rep. 2017; 19(10):1997-2004. PMC: 5469939. DOI: 10.1016/j.celrep.2017.05.035. View

20.

Francque S, Bedossa P, Ratziu V, Anstee Q, Bugianesi E, Sanyal A . A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021; 385(17):1547-1558. DOI: 10.1056/NEJMoa2036205. View